M&T Bank Corp grew its stake in IQVIA Holdings Inc. (NYSE:IQV – Get Rating) by 8.5% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 114,197 shares of the medical research company’s stock after purchasing an additional 8,955 shares during the quarter. M&T Bank Corp’s holdings in IQVIA were worth $26,402,000 as of its most recent SEC filing.
Several other large investors also recently modified their holdings of the stock. Riverview Trust Co acquired a new position in shares of IQVIA in the first quarter valued at about $25,000. UMB Bank N A MO acquired a new position in shares of IQVIA in the fourth quarter valued at about $26,000. Dividend Assets Capital LLC acquired a new stake in IQVIA during the first quarter worth about $27,000. Johnson Financial Group Inc. acquired a new stake in IQVIA during the fourth quarter worth about $34,000. Finally, Catalyst Capital Advisors LLC acquired a new stake in IQVIA during the fourth quarter worth about $38,000. 87.12% of the stock is owned by institutional investors.
IQVIA Stock Up 0.2 %
Shares of NYSE IQV opened at $234.74 on Friday. The company has a 50 day simple moving average of $216.94 and a 200 day simple moving average of $223.66. The firm has a market cap of $43.78 billion, a PE ratio of 39.19, a price-to-earnings-growth ratio of 2.14 and a beta of 1.32. IQVIA Holdings Inc. has a 1 year low of $194.67 and a 1 year high of $285.61. The company has a debt-to-equity ratio of 2.36, a current ratio of 0.96 and a quick ratio of 0.96.
Analyst Upgrades and Downgrades
IQV has been the topic of a number of analyst reports. Barclays reduced their price objective on shares of IQVIA from $240.00 to $236.00 and set an “overweight” rating on the stock in a research note on Wednesday, July 13th. Piper Sandler upgraded shares of IQVIA from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $231.00 to $255.00 in a research note on Thursday, April 28th. Deutsche Bank Aktiengesellschaft increased their price objective on shares of IQVIA from $250.00 to $290.00 and gave the stock a “buy” rating in a research note on Tuesday, April 12th. StockNews.com downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Wednesday, July 13th. Finally, Evercore ISI raised their price target on shares of IQVIA from $265.00 to $275.00 in a research note on Friday, July 22nd. Two investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $274.44.
IQVIA Holdings Inc provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
- Get a free copy of the StockNews.com research report on IQVIA (IQV)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- Why Apple Could Be At All-Time Highs By Year End
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.